OpinionOpen Access

Duration of Biphoshonate Therapy in Osteoporosis: Where Do We Stand Today?

Volume 2 - Issue 4

Hande Mefkure Ozkaya*

Author Information Open or Close
- Department of Endocrinology and Metabolism, University of Health Sciences, Turkey
*Corresponding author: Hande Mefkure Ozkaya, Department of Endocrinology and Metabolism, Okmeydani Training and Research Hospital, University of Health Sciences, 34384, Okmeydani, Istanbul, Turkey

Received: February 13, 2018; Published: February 26, 2018

DOI: 10.26717/BJSTR.2018.02.000796

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Despite recent advances in treatment of osteoporosis and the availability of new agents bisphosphonates are still the cornerstone of osteoporosis treatment due to their safety, efficacy and relatively reasonable costs. On the other hand, the presence of rare side effects has brought to the agenda that these drugs should be given during limited time periods. The current approach is to perform dynamic risk identification in patients and to determine the type and duration of the treatment accordingly.

Keywords: Biphosphonate; Osteoporosis; Safety

Abbreviations: FIT: Fracture Intervention Trial; BMD: Bone Mineral Density; VERT: The Vertebral Efficacy with Risedronate Therapy; FDA: Food and Drug Administration; FLEX: The Fracture Intervention Trial Long term extension.

Abstract| Introduction| Conclusion| References|